CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles

Pharmacogenetics

Volumn 8, Issue 6, 1998, Pages 529-541

  Leathart, Julian B S ^a,b   London, Stephanie J ^c   Steward, Annette ^a   Adams, James D ^b   Idle, Jeffrey R ^a   Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Univ of Newcastle Medical School ^*

Author keywords

CYP2D6; Cytochrome P450; Debrisoquine; Polymorphism

Indexed keywords

CYTOCHROME P450; DEBRISOQUINE;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME METABOLISM; GENE FREQUENCY; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; NEGRO; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RACE DIFFERENCE; SINGLE STRAND CONFORMATION POLYMORPHISM; UNITED STATES;

EID: 0032421471     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199812000-00010     Document Type: Article

References (44)

1. Agundez JAG, Ledesma MC, Ladero JM, Benitez, J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995; 57:265-269.
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelmann-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278:441-446.
3. Armstrong M, Idle JR, Daly AK. A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Hum Genet 1993; 91:616-617.
4. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994; 4:73-81.
5. Bertilsson L, Dahl M-L, Sjoqvist F, Aberg-Wistedt A, Humble M, Johansson I, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63.
6. Chen S, Chou W-H, Blouin RA, Mao Z, Humphries LL, Meek QC, et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Immunol Ther 1997; 60:522-534.
7. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. Trends Pharmacol Sci 1992; 13:434-438.
8. Cotton RGH. Slowly but surely towards better scanning for mutations. Trends Genet 1997; 13:43-46.
9. Dahl ML, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjoqvist F. Ultarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995; 274:516-520.
10. Daly AK, Armstrong M, Monkman SC, Idle MM, Idle JR. The genetic and metabolic criteria for the assignment of debrisoquine hydroxylation (cytochrome P450IID6) phenotypes. Pharmacogenetics 1991; 1:33-41.
11. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102(suppl 9): 55-61.
12. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995; 73:539-554.
13. Daly AK, Brockmöller J, Broly F, Michelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996a; 6:193-211.
14. Daly AK, Fairbrother KS, Andreassen OA, Idle JR, Steen VM. Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 1996b; 6: 319-328.
15. Daly AK, Steen VM, Fairbrother KS, Idle JR. CYP2D6 multiallelism. Methods Enzymol 1996c; 272:199-210.
16. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 1980; 17:102-105.
17. Evans WE, Relling MV, Rahman A, McLeod HL, Scott EP, Lin J-S. Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypcs in black Americans. J Clin Invest 1993; 91:2150-2154.
18. Evert B, Griese E-U, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350:434-439.
19. Gonzalez FJ, Idle JR. Pharmacogenetic phenotyping and genotyping. Present status and future potential. Clin Pharmacokinet 1994; 26:59-70.
20. 14C] debrisoquine in man. Br J Clin Pharmacol 1979; 7:257-266.
21. Iyun AO, Lennard MS, Tucker GT, Woods HF. Metoprolol and debrisoquin metabolism in Nigerians - lack of evidence for polymorphic oxidation. Clin Pharmacol Ther 1986; 40:387-394.
22. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjoqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-11829.
23. Johansson I, Oscarson M, Yue Q-Y, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46:452-259.
24. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP20) locus: sequence and identification of a polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989; 45:889-905.
25. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995; 56:2285-2298.
26. Lennard MS, Iyun AO, Jackson PR, Tucker GT, Woods HF. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics 1992; 2:89-92.
27. London SJ, Daly AK, Leathart JBS, Navidi WC, Carpenter CC, Idle JR. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles county. Carcinogenesis 1997a; 18:1203-1214.
28. London S, Daly A, Leathart J, Adams J, Idle J. CYP2D6 phenotype and lung cancer risk. Proc Am Assoc Cancer Res 1997b; 37:461.
29. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995; 5:305-311.
30. Marez D, Legrand M, Sabbagh N, Lo-Guidice J-M, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996; 97:668-670.
31. Marez D, Legrand M, Sabbagh N, Lo Guidice J-M, Spire C, Lafitte J-J, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202.
32. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M. A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 1996; 42:713-719.
33. Mbanefo C, Bababunmi KA, Mahgoub A, Sloan TP, IdIe JR, Smith RL. A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. Xenobiotica 1980; 10:811-818.
34. Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alteration in enzyme function. Mol Pharmacol 1997; 52:1034-1040.
35. Panserat S, Mura C, Gerard N, Vincent-Viry M, Galteau MM, Jacqz-Aigrain E, Krishnamoorthy R. An unequal cross-over event within the CYP2D gene cluster generates a chimeric CYP2D7/CYP2D6 gene which is associated with the poor metabolizer phenotype. Br J Clin Phannacol 1995; 40:361-367.
36. Pease A, Solas D, Sullivan EJ, Cronin MT, Holmes C, Fodor SPA. Light-generated oligonucleotide arrays for rapid DNA sequence analysis. Proc Natl Acad Sci USA 1994; 91:5022-5026.
37. Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50:308-313.
38. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
39. Sambrook J, Fritsch EF, Maniatis T. Molecular clonong. A laboratory manual. Cold Spring Harbor Laboratory Press: 1989.
40. Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surveys 1995; 25:27-65.
41. de Sommers K, Moncrieff J, Avenant J. Non-correlations between debrisoquine and metoprolol polymorphisms in the Venda. Human Toxicol 1989; 8:365-368.
42. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A, et al. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994; 4:47-57.
43. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53:410-418.
44. Woolhouse NM, Eichelbaum M, Oates NR, Idle JR, Smith RO. Dissociation of co-regulatory control of debrisoquine/phenformin and sparteine oxidation in Ghanians. Clin Pharmacol Ther 1975; 37:512-521.